Of note, the PD-1-targeting monoclonal antibody (mAb) pembrolizumab has recently even been approved to replace chemotherapy in the first-line therapy of NSCLC with high expression of PD-L1 [10]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.